Want a lab? Here you go........
University of Massachusetts has a lab. Northeastern University (MA) has a lab, Brigham Womens Cancer Center has a lab. Dana Farber Cancer Clinic has a lab.
Here's a recent abstract for you to mull over....
Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids
Wilfred Ngwa1, 2*, Rajiv Kumar1, 3, Michele Moreau1, 2, Raymond Dabney4 and Allen Herman4
1Radiation, Dana-Farber/Brigham and Women's Cancer Center, United States
2University of Massachusetts Lowell, United States
3Northeastern University, United States
4Cannabis Science Inc, United States
Nanotechnology has opened up a new, previously unimaginable world in cancer diagnosis and therapy, leading to the emergence of Cancer Nanomedicine and nanoparticle-aided radiotherapy. Smart nanomaterials (nanoparticle drones) can now be constructed with capability to precisely target cancer cells and be remotely activated with radiation to emit micrometer-range missile-like electrons to destroy the tumor cells. These nanoparticle drones can also be programmed to deliver therapeutic payloads to tumor sites to achieve optimal therapeutic efficacy. In this article we examine the state-of-the-art and potential of nanoparticle drones in targeting lung cancer. Inhalation (air) versus traditional intravenous (‘sea’) routes of navigating physiological barriers using such drones is assessed. Results and analysis suggest that inhalation route may offer more promise for targeting tumor cells with radiosensitizers and cannabinoids from the perspective of maximizing damage to lung tumors cells while minimizing any collateral damage or side effects.
Keywords: smart nanoparticles (drones), Radiotherapy, Radiosensitizers, Cannabinoids, Inhalation, Intravenous delivery, lung cancer, therapeutic efficacy
Received: 27 Jun 2017; Accepted: 24 Aug 2017.
John Varlotto, University of Massachusetts Medical Center, United States
Shiv K. Gupta, Mayo Clinic Minnesota, United States
Wenyin Shi, Thomas Jefferson University, United States
Copyright: © 2017 Ngwa, Kumar, Moreau, Dabney and Herman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Here's pr to go with it.
Cannabis Science Announces Publication of Initial Research Results Using Nanoparticle Drones to Target Lung Cancer With Radiosensitizers and Cannabinoids in the Renowned Journal Frontiers in Oncology
BY MARKETWIRED .
SEPTEMBER 14, 2017 08:06 AM EDT
IRVINE, CA -- (Marketwired) -- 09/14/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal Frontiers in Oncology
The abstract can be viewed at:
This publication titled, "Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids," addresses drug delivery, and highlights an innovative strategy to transport cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts. The article is an initial result of burgeoning CBIS collaborative work and speaks to a key conclusion from the National Academies of Sciences, Engineering, and Medicine 2017 Report on The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research.
This report can be viewed at:
"The laboratory work from CBIS' collaborations are moving apace and more results are to be reported soon," stated Mr. Raymond C. Dabney, Cannabis Science Inc., President & CEO, Co-Founder. "Currently, early results show that using smart drug-delivery systems to deliver cannabinoids directly to tumor cells leads to increased tumor cell kill in animal models of lung cancer and pancreatic cancer, which are some of the deadliest cancers." These results are being prepared for publication and presentation at upcoming national and international conferences.
The innovative drug delivery strategy for cannabinoids is consistent with the three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of cannabinoids being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions.
"This publication reflects our initial work and we are assiduously working on using our drug delivery system to examine the effect of cannabinoids with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the FDA. As we continue this work we will expand our pharmaceutical development program from farm to bedside," said Allen A. Herman, MD, Ph.D. Cannabis Science Inc., Chief Medical Officer (CMO).
"The field of cannabinoids is expanding rapidly and there are several models of drug development being proposed. We believe that our program that combines the agricultural disciplines of effective and efficient growing of hemp and cannabis; the careful quality assured way of extracting active cannabinoids; and providing these cannabinoids to our scientists to conduct both laboratory and clinical studies presents a robust approach to cannabinoid development," concludes. Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS- NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Allen A. Herman MD, Ph.D.
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
Published September 14, 2017
Copyright © 2017 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.